More problematic is the treatment of TNBC, which accounts for 10–15% of BC cases and is characterised by limited possibilities for targeted therapy, as TNBC cells do not overexpress estrogen, progesterone, or HER2/neu receptors. The gene discussed is ERBB2; the disease is breast cancer.